Non-Alcoholic Steatohepatitis


Sterotherapeutics is developing treatment (ST-001) for Non-alcoholic Steatohepatitis (NASH) which has been predicted as the next major health epidemic. The situation is paramount as NASH has no approved treatments and is a leading cause of liver related morbidity and mortality. Analysts are forecasting that the market for NASH treatment could reach $35-$40 Billion by 2025.